EUCTR2008-001265-28-IT进行中（未招募）不适用
Open Label Extension (OLE) for the patients treated in the ISD002-P144-07 study with P144 topical administration for skin fibrosis in patients with systemic sclerosis - ND
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ISDIN S.A.
- 入组人数
- 98
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Previous participation and finalization of treatment period of the ISD002-P144-07 study without clinical relevant safety issues medically evaluated by the investigator. 2. For female subjects with childbearing potential: use of a known highly effective method of birth control, defined as those which results in a low failure rate: i.e. less 1% per year, (contraceptive pills, intrauterine contraceptive device, implants, vasectomized partner or sexual abstinence), for at least the extension study period and one month after the end of the extension study. 3. For male subjects with partners of childbearing potential: use of appropriate contraceptive methods (vasectomy, condoms or sexual abstinence), for at least the extension study period and one month after the end of the extension study. 4. Stable therapy for at least one month, except in the case of patients under treatment with putative disease modifying agents (immunosupressants like cyclophosphamide, or azathioprine) that will need at least three months of stable therapy, without the expectation of treatment modifications during the trial period.. 5. Capable of understanding and willing to provide signed and dated written voluntary informed consent before any protocol specific procedures are performed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Other skin diseases affecting the treatment area which could have been diagnosed during the ISD002-P144-07 study. 2. Woman became pregnant during the ISD002-P144-07 study. 3. Any new diagnosis since the ISD002-P144-07 study which includes: systemic sclerosis sine scleroderma, localized escleroderma, eosinophilic fascitis, or eosinophilia myalgia syndrome; any other definable connective tissue disease, such as rheumatoid arthritis, systemic lupus erythematosus, polymyositis, or dermatomyositis; clinically significant overlap condition; significant existing internal organ damage as defined in the guidelines for clinical trials in systemic sclerosis; history of skin cancer; other skin diseases affecting the treatment area. 4. Substantial history of environmental exposure to tainted rapeseed oil, vinyl chloride, L- tryptophan, bleomycin, trichoroethylene, or silica; PUVA therapy within 1 month of study drug initiation; concurrent interventional therapy that might independently influence outcome of trial, such as D-penicillamine, cyclosporine, methotrexate, interferon or photopheresis; topical corticosteroids treatment affecting the selected area; cosmetics over the treatment area.
研究者
相似试验
进行中（未招募）
不适用
Open Label Extension (OLE) for the patients treated in the ISD002-P144-07 study with P144 topical administration for skin fibrosis in patients with systemic sclerosis - OLESkin fibrosis in patients with systemic sclerosisMedDRA version: 9.1Level: LLTClassification code 10039710Term: SclerodermaEUCTR2008-001265-28-GBISDI98
进行中（未招募）
不适用
Open Label Extension (OLE) for the patients treated in the ISD002-P144-07 study with P144 topical administration for skin fibrosis in patients with systemic sclerosis.Az ISD002-P144-07 vizsgálat nyílt kiterjesztése P144-gyel kezelt, szisztémás szklerózisban szenvedo betegek felületi borfibrózisának kezelésében. - OLESkin fibrosis in patients with systemic sclerosis.Szisztémás szklerózisban szenvedo betegek.MedDRA version: 9.1Level: LLTClassification code 10039710Term: SclerodermaEUCTR2008-001265-28-HUISDI98
进行中（未招募）
1 期
ong-term, open-label (dose-blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine - REJOIMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersMigraineEUCTR2020-001649-38-PTH. Lundbeck A/S645
进行中（未招募）
1 期
A long-term extension study of a new investigational medicinal product for the treatment of Duchenne Muscular Dystrophy patientsPatients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53SkippingMedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-004625-32-ESSarepta Therapeutics, Inc.150
进行中（未招募）
1 期
A long-term extension study of a new investigational medicinal product for the treatment of Duchenne Muscular Dystrophy patientsEUCTR2017-004625-32-CZSarepta Therapeutics, Inc.260